Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.09M
Average 0.17M
BLTE Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Belite Bio, IncNASDAQ: BLTE
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation outflow grows to $6.78K
Q2 FY2026 stock-based compensation was $6.78K, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $45.7K. Over 3 fiscal years it compounded at +197.2% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $6.78K or moves back toward the trailing-twelve-month quarterly average of $11.43K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 38.92M USD
- Year-over-year change
- +333.1%
- 4-year CAGR
- +124.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.92M | +333.1% |
| FY2024 | 2024-12-31 | 8.99M | +135.1% |
| FY2023 | 2023-12-31 | 3.82M | +157.8% |
| FY2022 | 2022-12-31 | 1.48M | -3.1% |
| FY2021 | 2021-12-31 | 1.53M | — |
Stock-Based Compensation vs competitors
How BLTE compares with its peers on the latest reported figures
- BLTE's LTM Jun 2026 stock-based compensation of $45.7K is the smallest of the 6 companies compared; the peer median is $9.22M.
- Its year-over-year change of +408.5% is the highest of 5, against a peer median of +19.0%.
- Over three fiscal years its annual growth of +197.2% compares with a peer median of +6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $63.89M | +17.9% | -17.8% | — | |
| LTM Mar 2026 | $31.69M | -0.5% | +25.3% | 416.2% | |
| LTM Mar 2026 | $9.22M | +22.1% | -9.9% | 206.5% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M | +20.1% | +23.4% | 33.0% |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $638K | — | — | — |
BLTEBelite Bio, Inc | LTM Jun 2026 | $45.7K | +408.5% | +197.2% | — |
| Peer median (excluding BLTE) | $9.22M | +19.0% | +6.8% | 206.5% | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| Deferred Income Tax | 0 | (1.91M) | (4.69M) | 0 | 0 |
| Stock-Based Compensation | 1.53M | 1.48M | 3.82M | 8.99M | 38.92M |
| Change in Working Capital | 640K | (491K) | (2.43M) | 1.13M | 2.55M |
| Accounts Receivables | 0 | (32K) | (72K) | 74K | (66K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 640K | (459K) | (2.36M) | 1.06M | 2.62M |
| Other Non-Cash Items | (8K) | 1.91M | 4.69M | (3.66M) | (1.31M) |
| Operating Cash Flow | (7.47M) | (11.46M) | (29.84M) | (29.23M) | (36.99M) |
| Capital Expenditures | (74K) | (394K) | (63K) | (151K) | (178K) |
| Acquisitions (Net) | 18K | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (188.27M) | (451.99M) |
| Sales of Investments | 0 | 0 | 0 | 77.84M | 147.07M |
| Other Investing Activities | 0 | 0 | 0 | (35K) | 0 |
| Investing Cash Flow | (56K) | (394K) | (63K) | (110.57M) | (305.11M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (583K) | 37.99M | 77.19M | 42.24M | 292.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.03M) | (1.23M) | 41.36M | 370.37M |
| Financing Cash Flow | (583K) | 36.96M | 75.96M | 83.6M | 663.23M |
| Effect of Forex Changes | (161K) | (366K) | 9K | (269K) | 117K |
| Net Change in Cash | (8.27M) | 24.75M | 46.07M | (56.48M) | 321.26M |
| Free Cash Flow | (7.55M) | (11.85M) | (29.9M) | (29.39M) | (37.17M) |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.